RecruitingPhase 1NCT06119256

Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

Multicenter, Open Label, Single-arm Exploratory Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

Sponsor

Chinese PLA General Hospital

Enrollment

12 participants

Start Date

Aug 1, 2023

Study Type

INTERVENTIONAL

Conditions

EBV Infection After Allogenic HSCT

Summary

This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.

Eligibility

Min Age: 14 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called EBV-TCR-T cells for people with ebv infection after allogenic hsct. The study is currently recruiting participants at 1 location. People eligible for this study include aged 14 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALEBV-TCR-T cells

The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.

Locations(1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06119256